Spencer and Davie: Dynamic histone acetylation and its involvement in transcriptionA recent study mapping the distribution of di-methylatedlysine 9 on H3 across the chicken β-globin domain duringerythropoiesis showed that regions enriched in methylatedlysine 9 were depleted of di-acetylated H3 (K9 and K14).However, H3 acetylation correlated with lysine 4methylation, suggesting that transcriptional activation isassociated with H3 methylated at K4, as well as withacetylated H3 and H4 isoforms (Litt et al, 2001).Likewise, in Tetrahymena, methylated Lys4 of H3 isfound only in transcriptionally active macronuclei (Strahlet al, 1999).AcknowledgmentsResearch supported by grants from the CanadianInstitutes of Health Research (CIHR) (MT-9186,RO-15183), CancerCare Manitoba, and the U.S. ArmyMedical and Materiel Command Breast Cancer ResearchProgram (#DAM17-00-1-0319), and the National CancerInstitute of Canada with funds from the Canadian CancerSociety. A CIHR Senior Scientist Award to J.R.D. and aU.S. Army Medical and Materiel Command Fellowship toV.A.S. are gratefully acknowledged.ReferencesAfshar G, and Murnane JP (1999) Characterization of a humangene with sequence homology to Saccharomyces cerevisiaeSIR2. <strong>Gene</strong> 234, 161-168.Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T, andThanos D (2000) Ordered recruitment of chromatinmodifying and general transcription factors to the IFN-βpromoter. Cell 103, 667-678.Annunziato AT, and Hansen J C (2000) Role of histoneacetylation in the assembly and modulation of chromatinstructures. <strong>Gene</strong> Expr 9, 37-61.Bannister AJ, Miska EA, Gorlich D, and Kouzarides T (2000)Acetylation of importin-alpha nuclear import factors byCBP/p300. Curr Biol 10, 467-470.Barbaric S, Walker J, Schmid A, Svejstrup JQ, and Horz W(2001) Increasing the rate of chromatin remodeling and geneactivation--a novel role for the histone acetyltransferaseGcn5. EMBO J 20, 4944-4951.Berger SL (2001) An embarrassment of niches: the manycovalent modifications of histones in transcriptionalregulation. Oncogene 20, 3007-3013.Bertos NR, Wang AH, and Yang XJ (2001) Class II histonedeacetylases: structure, function, and regulation. BiochemCell Biol 79, 243-252.Boisvert FM, Kruhlak MJ, Box AK, Hendzel MJ, and Bazett-Jones DP (2001) The transcription coactivator CBP is adynamic component of the promyelocytic leukemia nuclearbody. J Cell Biol 152, 1099-1106.Braunstein M, Sobel RE, Allis CD, Turner BM, and Broach JR(1996) Efficient transcriptional silencing in Saccharomycescerevisiae requires a heterochromatin histone acetylationpattern. Mol Cell Biol 16, 4349-4356.Bustin M (1999) Regulation of DNA-dependent activities by thefunctional motifs of the high-mobility-group chromosomalproteins. Mol Cell Biol 19, 5237-5246.Cairns BR, Schlichter A, Erdjument-Bromage H, Tempst P,Kornberg RD, and Winston F (1999) Two functionallydistinct forms of the RSC nucleosome-remodeling complex,containing essential AT hook, BAH, and bromodomains.Mol Cell 4, 715-723.Cervoni N and Szyf M (2001) Demethylase activity is directedby histone acetylation. J Biol Chem 276, 40778-40787.Chen H, Lin RJ, Xie W, Wilpitz D, and Evans RM (1999)Regulation of hormone-induced histone hyperacetylation andgene activation via acetylation of an acetylase. Cell 98, 675-686.Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM,and Allis CD (2000) Synergistic coupling of histone H3phosphorylation and acetylation in response to epidermalgrowth factor stimulation. Mol Cell 5, 905-915.Cho H, Orphanides G, Sun X, Yang XJ, Ogryzko V, Lees E,Nakatani Y, and Reinberg D (1998). A human RNApolymerase II complex containing factors that modifychromatin structure. Mol Cell Biol 18, 5355-5363.Covault J and Chalkley R (1980) The identification of distinctpopulations of acetylated histone. J Biol Chem 255, 9110-9116.Crane-Robinson C, Myers FA, Hebbes TR, Clayton AL, andThorne AW (1999). Chromatin immunoprecipitation assaysin acetylation mapping of higher eukaryotes. MethodsEnzymol 304, 533-547.Davie JR (1995) The nuclear matrix and the regulation ofchromatin organization and function. Int Rev Cytol 162A,191-250.Davie JR and Moniwa M (2000) Control of chromatinremodeling. Crit Rev Eukaryot <strong>Gene</strong> Expr 10, 303-325.Davie JR and Spencer VA (1999) Control of histonemodifications. J Cell Biochem Suppl 32-33, 141-148.Davie JR and Spencer VA (2001) Signal transduction pathwaysand the modification of chromatin structure. Prog NucleicAcid Res Mol Biol 65, 299-340.De Rubertis F, Kadosh D, Henchoz S, Pauli D, Reuter G, StruhlK, and Spierer P (1996) The histone deacetylase RPD3counteracts genomic silencing in Drosophila and yeast.Nature 384, 589-591.Downes M, Ordentlich P, Kao HY, Alvarez JG, and Evans RM(2000) Identification of a nuclear domain with deacetylaseactivity. Proc Natl Acad Sci USA 97, 10330-10335.Fisher AL and Caudy M (1998) Groucho proteins: transcriptionalcorepressors for specific subsets of DNA-bindingtranscription factors in vertebrates and invertebrates. <strong>Gene</strong>sDev 12, 1931-1940.Frye RA (1999) Characterization of five human cDNAs withhomology to the yeast SIR2 gene: Sir2-like proteins (sirtuins)metabolize NAD and may have protein ADPribosyltransferaseactivity. Biochem Biophys Res Commun260, 273-279.Frye RA (2000) Phylogenetic classification of prokaryotic andeukaryotic Sir2-like proteins. Biochem Biophys ResCommun 273, 793-798.Garcia-Ramirez M, Rocchini C, and Ausio J (1995) Modulationof chromatin folding by histone acetylation. J Biol Chem270, 17923-17928.Grant PA, Eberharter A, John S, Cook RG, Turner BM, andWorkman JL (1999) Expanded lysine acetylation specificityof Gcn5 in native complexes. J Biol Chem 274, 5895-5900.Gregory PD, Schmid A, Zavari M, Munsterkotter M, and HorzW (1999) Chromatin remodeling at the PHO8 promoterrequires SWI-SNF and SAGA at a step subsequent toactivator binding. EMBO J 18, 6407-6414.10
<strong>Gene</strong> <strong>Therapy</strong> and <strong>Molecular</strong> <strong>Biology</strong> Vol 7, page 11Grunstein M (1998) Yeast heterochromatin: regulation of itsassembly and inheritance by histones. Cell 93, 325-328.Gu W and Roeder RG (1997) Activation of p53 sequencespecificDNA binding by acetylation of the p53 C-terminaldomain. Cell 90, 595-606.Guardiola AR and Yao TP (2002) <strong>Molecular</strong> cloning andcharacterization of a novel histone deacetylase HDAC10. JBiol Chem 277, 3350-3356.Hansen JC (1997) The core histone amino-termini: combinatorialinteraction domains that link chromatin structure withfunction. Chemtracts Biochem Mol Biol 10, 56-69.Hansen JC, Tse C, and Wolffe AP (1998) Structure and functionof the core histone N-termini: more than meets the eye.Biochemistry 37, 17637-17641.Hasan S, Stucki M, Hassa PO, Imhof R, Gehrig P, Hunziker P,Hubscher U, and Hottiger MO (2001) Regulation of humanflap endonuclease-1 activity by acetylation through thetranscriptional coactivator p300. Mol Cell 7, 1221-1231.Hassan AH, Neely KE, and Workman JL (2001) Histoneacetyltransferase complexes stabilize swi/snf binding topromoter nucleosomes. Cell 104, 817-827.Hebbes TR and Allen SC (2000) Multiple histoneacetyltransferases are associated with a chicken erythrocytechromatin fraction enriched in active genes. J Biol Chem275, 31347-31352.Hebbes TR, Clayton AL, Thorne AW, and Crane-Robinson C(1994) Core histone hyperacetylation co-maps withgeneralized DNase I sensitivity in the chicken β-globinchromosomal domain. EMBO J 13, 1823-1830.Hendzel MJ, Delcuve GP, and Davie JR (1991) Histonedeacetylase is a component of the internal nuclear matrix. JBiol Chem 266, 21936-21942.Herrera JE, Sakaguchi K, Bergel M, Trieschmann L, Nakatani Y,and Bustin M (1999) Specific acetylation of chromosomalprotein HMG-17 by PCAF alters its interaction withnucleosomes. Mol Cell Biol 19, 3466-3473.Hung HL, Lau J, Kim AY, Weiss MJ, and Blobel GA (1999)CREB-Binding protein acetylates hematopoietic transcriptionfactor GATA-1 at functionally important sites. Mol Cell Biol19, 3496-3505.Imai S, Armstrong CM, Kaeberlein M, and Guarente L (2000)Transcriptional silencing and longevity protein Sir2 is anNAD-dependent histone deacetylase. Nature 403, 795-800.Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, andGe H (1997) Acetylation of general transcription factors byhistone acetyltransferases. Curr Biol 7, 689-692.Jenuwein T and Allis CD (2001) Translating the histone code.Science 293, 1074-1080.Johnson CA, O'Neill LP, Mitchell A, and Turner BM (1998)Distinctive patterns of histone H4 acetylation are associatedwith defined sequence elements within both heterochromaticand euchromatic regions of the human genome. NucleicAcids Res 26, 994-1001.Kadosh D and Struhl K (1998) Targeted recruitment of the Sin3-Rpd3 histone deacetylase complex generates a highlylocalized domain of repressed chromatin in vivo. Mol CellBiol 18, 5121-5127.Kimura H and Cook PR (2001) Kinetics of core histones inliving human cells: little exchange of H3 and H4 and somerapid exchange of H2B. J Cell Biol 153, 1341-1353.Kingston RE and Narlikar GJ (1999) ATP-dependent remodelingand acetylation as regulators of chromatin fluidity. <strong>Gene</strong>sDev 13, 2339-2352.Klochendler-Yeivin A and Yaniv M (2001). Chromatin modifiersand tumor suppression. Biochim Biophys Acta 1551, M1-10.Kouzarides T (2000) Acetylation: a regulatory modification torival phosphorylation? EMBO J 19, 1176-1179.Krebs JE, Kuo MH, Allis CD, and Peterson CL (1999) Cellcycle-regulated histone acetylation required for expression ofthe yeast HO gene. <strong>Gene</strong>s Dev 13, 1412-1421.Kruhlak MJ, Hendzel MJ, Fischle,W, Bertos NR, Hameed S,Yang XJ, Verdin E, and Bazett-Jones DP (2001) Regulationof global acetylation in mitosis through loss of histoneacetyltransferases and deacetylases from chromatin. J BiolChem 276, 38307-38319.Kuo MH and Allis CD (1998) Roles of histone acetyltransferasesand deacetylases in gene regulation. Bioessays 20, 615-626.L'Hernault SW and Rosenbaum JL (1985) Chlamydomonasalpha-tubulin is posttranslationally modified by acetylationon the epsilon-amino group of a lysine. Biochemistry 24,473-478.Litt MD, Simpson M, Gaszner M, Allis CD, and Felsenfeld G(2001) Correlation between histone lysine methylation anddevelopmental changes at the chicken β-globin locus.Science 293, 2453-2455.Landry J, Slama JT, and Sternglanz R (2000) Role of NAD(+) inthe deacetylase activity of the SIR2-like proteins. BiochemBiophys Res Commun 278, 685-690.Lee,HJ, Chun M, and Kandror KV (2001) Tip60 and HDAC7interact with the endothelin receptor a and may be involvedin downstream signaling. J Biol Chem 276, 16597-16600.Leuba SH, Bustamante C, van Holde K, and Zlatanova J (1998a)Linker histone tails and N-tails of histone H3 are redundant:scanning force microscopy studies of reconstituted fibers.Biophys J 74, 2830-2839.Leuba SH, Bustamante C, Zlatanova J, and van Holde K (1998b)Contributions of linker histones and histone H3 to chromatinstructure: scanning force microscopy studies on trypsinizedfibers. Biophys J 74, 2823-2829.Liu YZ, Thomas NS, and Latchman DS (1999) CBP associateswith the p42/p44 MAPK enzymes and is phosphorylatedfollowing NGF treatment. Neuroreport 10, 1239-1243.Lo WS, Duggan L, Tolga NC, Emre, Belotserkovskya R, LaneWS, Shiekhattar R, and Berger SL. (2001) Snf1--a histonekinase that works in concert with the histoneacetyltransferase Gcn5 to regulate transcription. Science 293,1142-1146.Lo WS, Trievel RC, Rojas JR, Duggan L, Hsu JY, Allis CD,Marmorstein R, and Berger SL (2000) Phosphorylation ofserine 10 in histone H3 is functionally linked in vitro and invivo to Gcn5-mediated acetylation at lysine 14. Mol Cell 5,917-926.Logie C, Tse C, Hansen JC, and Peterson CL (1999) The corehistone N-terminal domains are required for multiple roundsof catalytic chromatin remodeling by the SWI/SNF and RSCcomplexes. Biochemistry 38, 2514-2522.Luger K, Mader AW, Richmond RK, Sargent DF, and RichmondTJ (1997) Crystal structure of the nucleosome core particle at2.8 A resolution. Nature 389, 251-260.Madisen L, Krumm A, Hebbes TR, and Groudine M (1998) Theimmunoglobulin heavy chain locus control region increaseshistone acetylation along linked c-myc genes. Mol Cell Biol18, 6281-6292.11
- Page 7 and 8: Instructions to authors:Gene Therap
- Page 9: Please submit an electronic version
- Page 12: 103-111 ResearchArticle113-133 Revi
- Page 17 and 18: Gene Therapy and Molecular Biology
- Page 19 and 20: Gene Therapy and Molecular Biology
- Page 21 and 22: Gene Therapy and Molecular Biology
- Page 23: Gene Therapy and Molecular Biology
- Page 27 and 28: Gene Therapy and Molecular Biology
- Page 29 and 30: Gene Therapy and Molecular Biology
- Page 31 and 32: Gene Therapy and Molecular Biology
- Page 33 and 34: Gene Therapy and Molecular Biology
- Page 35 and 36: Gene Therapy and Molecular Biology
- Page 37 and 38: Gene Therapy and Molecular Biology
- Page 39 and 40: Gene Therapy and Molecular Biology
- Page 41 and 42: Gene Therapy and Molecular Biology
- Page 43 and 44: Gene Therapy and Molecular Biology
- Page 45 and 46: Gene Therapy and Molecular Biology
- Page 47 and 48: Gene Therapy and Molecular Biology
- Page 49 and 50: Gene Therapy and Molecular Biology
- Page 51 and 52: Gene Therapy and Molecular Biology
- Page 53 and 54: Gene Therapy and Molecular Biology
- Page 55 and 56: Gene Therapy and Molecular Biology
- Page 57 and 58: Gene Therapy and Molecular Biology
- Page 59 and 60: Gene Therapy and Molecular Biology
- Page 61 and 62: Gene Therapy and Molecular Biology
- Page 63 and 64: Gene Therapy and Molecular Biology
- Page 65 and 66: Gene Therapy and Molecular Biology
- Page 67 and 68: Gene Therapy and Molecular Biology
- Page 69 and 70: Gene Therapy and Molecular Biology
- Page 71 and 72: Gene Therapy and Molecular Biology
- Page 73 and 74: Gene Therapy and Molecular Biology
- Page 75 and 76:
Gene Therapy and Molecular Biology
- Page 77:
Gene Therapy and Molecular Biology
- Page 80 and 81:
Epperly et al: Late injection of Mn
- Page 82 and 83:
Epperly et al: Late injection of Mn
- Page 84 and 85:
Goldberg-Cohen et al: Regulation of
- Page 86 and 87:
Goldberg-Cohen et al: Regulation of
- Page 88 and 89:
Goldberg-Cohen et al: Regulation of
- Page 90 and 91:
Gascón-Irún et al: Gene therapy a
- Page 92 and 93:
Gascón-Irún et al: Gene therapy a
- Page 94 and 95:
Gascón-Irún et al: Gene therapy a
- Page 96 and 97:
Gascón-Irún et al: Gene therapy a
- Page 98 and 99:
Gascón-Irún et al: Gene therapy a
- Page 100 and 101:
Gascón-Irún et al: Gene therapy a
- Page 102 and 103:
Gascón-Irún et al: Gene therapy a
- Page 104 and 105:
Gascón-Irún et al: Gene therapy a
- Page 106 and 107:
Suzuki et al: Regulation of the Sp/
- Page 108 and 109:
Suzuki et al: Regulation of the Sp/
- Page 110 and 111:
Suzuki et al: Regulation of the Sp/
- Page 112 and 113:
Suzuki et al: Regulation of the Sp/
- Page 114 and 115:
Li et al: MET amplification in live
- Page 116 and 117:
Li et al: MET amplification in live
- Page 118 and 119:
Chavakis et al: Leukocyte adhesion
- Page 120 and 121:
Chavakis et al: Leukocyte adhesion
- Page 122 and 123:
Chavakis et al: Leukocyte adhesion
- Page 124 and 125:
Chavakis et al: Leukocyte adhesion
- Page 126 and 127:
Chavakis et al: Leukocyte adhesion
- Page 128 and 129:
Sanlioglu et al: Adenovirus mediate
- Page 130 and 131:
Sanlioglu et al: Adenovirus mediate
- Page 132 and 133:
Sanlioglu et al: Adenovirus mediate
- Page 134 and 135:
Sanlioglu et al: Adenovirus mediate
- Page 136 and 137:
Sanlioglu et al: Adenovirus mediate
- Page 138 and 139:
Sanlioglu et al: Adenovirus mediate
- Page 140 and 141:
Sanlioglu et al: Adenovirus mediate
- Page 142 and 143:
Sanlioglu et al: Adenovirus mediate
- Page 144 and 145:
Sanlioglu et al: Adenovirus mediate
- Page 146 and 147:
Sanlioglu et al: Adenovirus mediate
- Page 148 and 149:
Sanlioglu et al: Adenovirus mediate
- Page 150 and 151:
George et al: Gene therapy for vasc
- Page 152 and 153:
George et al: Gene therapy for vasc
- Page 154 and 155:
George et al: Gene therapy for vasc
- Page 156 and 157:
George et al: Gene therapy for vasc
- Page 158 and 159:
George et al: Gene therapy for vasc
- Page 160 and 161:
George et al: Gene therapy for vasc
- Page 162 and 163:
George et al: Gene therapy for vasc
- Page 164 and 165:
George et al: Gene therapy for vasc
- Page 166 and 167:
George et al: Gene therapy for vasc
- Page 168 and 169:
Zhang et al: Angiogenic Gene Therap
- Page 170 and 171:
Zhang et al: Angiogenic Gene Therap
- Page 172 and 173:
Zhang et al: Angiogenic Gene Therap
- Page 174 and 175:
Zhang et al: Angiogenic Gene Therap
- Page 176 and 177:
Zhang et al: Angiogenic Gene Therap
- Page 178 and 179:
Zhang et al: Angiogenic Gene Therap
- Page 180 and 181:
Zhang et al: Angiogenic Gene Therap
- Page 182 and 183:
Xu et al: G-CSF receptor-mediated S
- Page 184 and 185:
Xu et al: G-CSF receptor-mediated S
- Page 186 and 187:
Xu et al: G-CSF receptor-mediated S
- Page 188 and 189:
Burek et al: Calcium induced cell d
- Page 190 and 191:
Burek et al: Calcium induced cell d
- Page 192 and 193:
Burek et al: Calcium induced cell d
- Page 194 and 195:
Burek et al: Calcium induced cell d
- Page 196 and 197:
David et al: Current status and fut
- Page 198 and 199:
David et al: Current status and fut
- Page 200 and 201:
David et al: Current status and fut
- Page 202 and 203:
David et al: Current status and fut
- Page 204 and 205:
David et al: Current status and fut
- Page 206 and 207:
David et al: Current status and fut
- Page 208 and 209:
David et al: Current status and fut
- Page 210 and 211:
David et al: Current status and fut
- Page 212 and 213:
David et al: Current status and fut
- Page 214 and 215:
David et al: Current status and fut
- Page 216 and 217:
David et al: Current status and fut
- Page 218 and 219:
David et al: Current status and fut
- Page 220 and 221:
David et al: Current status and fut
- Page 222 and 223:
David et al: Current status and fut
- Page 224 and 225:
David et al: Current status and fut
- Page 226 and 227:
Stoll et al: The role of EBV and ge
- Page 228 and 229:
Stoll et al: The role of EBV and ge
- Page 230 and 231:
Stoll et al: The role of EBV and ge
- Page 232 and 233:
Stoll et al: The role of EBV and ge
- Page 234 and 235:
Stoll et al: The role of EBV and ge
- Page 236 and 237:
Maruyama et al: Kidney-targeted pla
- Page 238 and 239:
Maruyama et al: Kidney-targeted pla
- Page 240 and 241:
Maruyama et al: Kidney-targeted pla
- Page 242 and 243:
Maruyama et al: Kidney-targeted pla
- Page 244 and 245:
Kren et al: Hepatocyte-targeted del
- Page 246 and 247:
Kren et al: Hepatocyte-targeted del
- Page 248 and 249:
Kren et al: Hepatocyte-targeted del
- Page 250 and 251:
Kren et al: Hepatocyte-targeted del
- Page 252 and 253:
Kren et al: Hepatocyte-targeted del
- Page 254 and 255:
Zeng: PRL-3 as a target for cancer
- Page 256 and 257:
Zeng: PRL-3 as a target for cancer
- Page 258 and 259:
Zeng: PRL-3 as a target for cancer
- Page 260 and 261:
Latchman: Protective effect of heat
- Page 262 and 263:
Latchman: Protective effect of heat
- Page 264 and 265:
Latchman: Protective effect of heat
- Page 266 and 267:
Latchman: Protective effect of heat
- Page 268 and 269:
Latchman: Protective effect of heat
- Page 270 and 271:
Cai et al: Lung cancer gene therapy
- Page 272 and 273:
Cai et al: Lung cancer gene therapy
- Page 274 and 275:
Cai et al: Lung cancer gene therapy
- Page 276 and 277:
Cai et al: Lung cancer gene therapy
- Page 278 and 279:
Cai et al: Lung cancer gene therapy
- Page 280:
Cai et al: Lung cancer gene therapy
- Page 283 and 284:
Gene Therapy and Molecular Biology
- Page 285 and 286:
Gene Therapy and Molecular Biology
- Page 287 and 288:
Gene Therapy and Molecular Biology
- Page 289 and 290:
Gene Therapy and Molecular Biology
- Page 291 and 292:
Gene Therapy and Molecular Biology
- Page 293 and 294:
Gene Therapy and Molecular Biology
- Page 295 and 296:
Gene Therapy and Molecular Biology
- Page 297 and 298:
Gene Therapy and Molecular Biology
- Page 299 and 300:
Gene Therapy and Molecular Biology
- Page 301 and 302:
Gene Therapy and Molecular Biology
- Page 303 and 304:
Gene Therapy and Molecular Biology
- Page 305 and 306:
Gene Therapy and Molecular Biology
- Page 307 and 308:
Gene Therapy and Molecular Biology
- Page 309:
Gene Therapy and Molecular Biology